A Framework for Developing Pharmacotherapy for Agitation in Alzheimer’s disease: Recommendations of the ISCTM Working Group - 21/11/24
, R. Khoury 2, A. Anderson 3, M. Carter 4, F. DiCesare 5, S. Dubé 6, L. Ereshefsky 7, G. Grossberg 2, N. Hefting 8, S. Khan 4, S. Lind 8, H. Moebius 9, T. Shiovitz 10, P. Rosenberg 11ISCTM: International Society for CNS Clinical Trials and Methodology
Plan
| Dedication: This article is dedicated to the memory of Dr. Brendon Binneman who contributed generously of his time and expertise in the early stages of this project. |
Vol 7 - N° 4
P. 274-282 - septembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
